Infectious disease

As a virus-infected model, the utilization of tonsil, adenoid, and lung organoids allows for the evaluation of antiviral drug efficacy and facilitates virus research.

*Please login to see the price

€ 0 +

Starting cost

Infectious disease

SARS-COV-2 infection model
(Tonsil organoid)

This model allows researchers to study the dynamics of viral entry, replication, and host response within the tonsil organoid system.
Lambda provides a comprehensive solution, offering the service of applying antiviral treatments such as Remdesivir.
This allows for an investigation into their therapeutic efficacy in reducing viral replication.

Cell Type

· ASC

Organoid type

· Tonsil organoid

SARS-COV-2 infection model (Adenoid organoid)

This model allows researchers to study the dynamics of viral entry, replication, and host response within the adenoid organoid system.
Lambda provides a comprehensive solution, offering the service of applying antiviral treatments.
This allows for an investigation into their therapeutic efficacy in reducing viral replication.

Cell Type

· ASC

Organoid type

· Adenoid organoid

Respiratory tract infection

Lung organoids, mimicking the human lung, are instrumental in respiratory infection research.
Lambda specifically employs patient-derived lung organoids for assessing the effectiveness of antiviral drugs.
This approach enhances our understanding of disease pathogenesis, aids in drug discovery, contributes to vaccine development, and provides a physiologically relevant platform for studying host-pathogen interactions.

Cell Type

· ASC

Organoid type

· Lung organoid

Request a quote

Assay

SARS-COV-2 infection model (Tonsil organoid)

The SARS-CoV-2 infection model using tonsil organoids involves exposing the organoids to the virus to simulate infection conditions.
This model allows researchers to study the dynamics of viral entry, replication, and host response within the tonsil organoid system.
Lambda provides a comprehensive solution, offering the service of applying antiviral treatments such as Remdesivir.
This allows for an investigation into their therapeutic efficacy in reducing viral replication.

Assay process

Step 1: Production and cultivation of tonsil organoids from tonsil tissue.
Step 2: Infection of tonsil organoids with SARS-CoV-2, and determination of viral titer through plaque assay.
Step 3: Treatment of SARS-CoV-2 infected tonsil organoids with the antiviral drug remdesivir.
Step 4: After treating the infected tonsil organoid with an antiviral drug, evaluate the efficacy of the antiviral drug by measuring the virus concentration in the organoid and checking the remaining virus.

Technical

SARS-CoV-2 Infection data(H&E/IF)

Virus infection (experimental conditions: MOCK, o.1 MOI, 1MOI) is confirmed by IF (Spike, dsRNA). At this time, ACE2 acts as a viral infection receptor.
Additionally, through titration, it can be confirmed that the virus enters the organoid and is amplified.

The therapeutic efficacy of Remdesivir against SARS-CoV-2 can be validated in tonsil organoids.
Reductions in the spike and nucleocapsid of the virus can be observed, and Immunofluorescence (IF) confirms a decrease in the spike protein.